Crescendo Biologics Ltd (Crescendo), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announces that senior members of the executive team will
Crescendo to Participate in Upcoming Investor Conferences financialbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialbuzz.com Daily Mail and Mail on Sunday newspapers.
Investegate |Poolbeg Pharma PLC Announcements | Poolbeg Pharma PLC: September and October Investor conferences investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Admission to AIM First day of trading Poolbeg Pharma (AIM: POLB), a clinical stage infectious disease pharmaceutical company with a capital light clinical model , is pleased to announce that admission of its entire issued share capital to trading on the AIM market of the London Stock Exchange will become effective and dealings will commence at 8.00 a.m. today under the ticker POLB and with the ISIN GB00BKPG7Z60 ( Admission ). The full Admission Document is available to view on the Company s website at www.poolbegpharma.com · Shares priced at 10p per share equating to a market capitalisation at Admission of £50m